

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

Provisional matrix of consultees and commentators

| Consultees | Commentators (no right to submit or appeal) |
|---|--|
| <p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> Ocular Therapeutix (dexamethasone intracanalicular insert) <p><u>Patient/carer groups</u></p> <p>Action for Blind People Eyecare Trust Fight for Sight Muslim Council of Britain National Federation of the Blind of the UK OBAC (Organisation of Blind African Caribbeans) Royal National Institute of Blind People (RNIB) SeeAbility Sense South Asian Health Foundation Specialised Healthcare Alliance Thomas Pocklington Trust</p> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> Association of Anaesthetists Association of Optometrists Association of Surgeons of Great Britain and Ireland British and Irish Orthoptic Society British Geriatrics Society British Ophthalmic Anaesthesia Society College of Optometrists Oxford Eye Foundation Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Ophthalmologists Royal College of Pathologists Royal College of Physicians | <p><u>General commentators</u></p> <ul style="list-style-type: none"> All Wales Therapeutic and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Clinical Council for Eye Health Commissioning Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Commercial Medicines Unit NHS Confederation Scottish Medicines Consortium Vision 2020 Ltd Wales Council for the Blind Welsh Health Specialised Services Committee Wales Ophthalmic Planned Care Board <p><u>Comparators</u></p> <ul style="list-style-type: none"> Allergan (flurbiprofen, fluorometholone, ketorolac, prednosolone) Cheisi (diclofenac) Concordia International (diclofenac) FDC International (hypromellose) Martindale Pharma (hypromellose) Novartis (dexamethasone, |

National Institute for Health and Care Excellence
Provisional matrix for the single technology appraisal of dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

| | |
|---|---|
| <ul style="list-style-type: none"> • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK and Ireland Society of Cataract and Refractive Surgeons <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Durham Dales, Easington and Sedgefield CCG • NHS England • NHS South Tyneside CCG • Welsh Government | <p>hypromellose, nepafenac)</p> <ul style="list-style-type: none"> • Rayner Pharmaceuticals (dexamethasone) • Thea Pharmaceuticals (dexamethasone, diclofenac) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Council for Prevention of Blindness • Cochrane Eyes and Vision Group • Eye Hope • Institute of Ophthalmology, University College London • MRC Clinical Trials Unit • National Eye Research Centre • National Institute for Health Research • NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital Foundation Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales |
|---|---|

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

STA Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.